Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

NCT04029272 · Unknown status

Last updated 2026-05-28

This clinical trial compares the effects of metformin alone versus metformin combined with a GLP-1 receptor agonist on body weight in overweight or obese patients with polycystic ovary syndrome.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 80 people Planned (estimated).

Who can join Ages 18–40 · female only

Timeline Started 2019-07 · est. completion 2020-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT04029272 ↗

Description as written by the study sponsor.

The purpose of this study was to determine whether metformin combined with exenatide once weekly (EQW) is more effective than metformin alone in the treatment of overweight/obese women with polycystic ovary syndrome (PCOS). Background therapies were Diane-35 or/and progesterone capsule. 80 participants were randomized to use either metformin or metformin+EQW for 12 weeks. Greater changes in body weight were anticipated in patients treated with EQW+metformin than metformin alone in those treated with metformin.

Treatments tested

Metformin also known as Glucophage Drug

500 mg tid for 12 weeks
Exenatide 2 MG also known as Bydureon Drug

Exenatide injection once weekly for 12 weeks

Main thing measured	Change in body weight
Sponsor	Peking Union Medical College Hospital
Conditions studied	Polycystic Ovary Syndrome
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04029272 ↗